Stocktoria
Cartesian Therapeutics, Inc. RNAC
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2016-06-22
Cartesian Therapeutics, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $2.8M | $38.9M | $26.0M | $110.8M | $85.1M |
| R&D expense | $58.0M | $45.1M | $71.3M | $72.4M | $68.7M |
| Operating income | -$143.4M | -$43.9M | -$86.4M | $14.5M | -$4.6M |
| Interest expense | — | — | $2.8M | $3.0M | $2.8M |
| Income tax | -$9.2M | $287,000 | -$19.0M | -$609,000 | $16.0M |
| Net income | -$130.3M | -$77.4M | -$219.7M | $35.4M | -$25.7M |
| EPS (diluted) | $-5.02 | $-4.49 | $-49.76 | $0.10 | $-0.22 |
| Operating cash flow | -$73.9M | -$23.7M | -$51.2M | -$31.6M | -$60.4M |
| Free cash flow | -$79.4M | -$32.8M | -$51.4M | -$32.8M | -$61.5M |
| Cash & equivalents | $125.1M | $212.6M | $76.9M | $106.4M | $114.1M |
| Total assets | $296.4M | $435.0M | $305.1M | $165.9M | $159.9M |
| Total liabilities | $422.7M | $441.8M | $444.7M | $72.1M | $137.4M |
| Shareholders' equity | -$126.2M | -$6.8M | -$440.2M | $93.8M | $22.5M |
Source: SEC EDGAR filings · CIK 0001453687 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.